Reporting adverse incidents: neurostimulators
For manufacturers reporting adverse incidents with neurostimulators under the vigilance system.
Latest change: Updated to reflect the laying of The Medical Devices (Post-market Surveillance requirements) (Amendment) Regulations 2024.
AI Summary
This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the mandatory reporting requirements for manufacturers regarding adverse incidents involving stimulator devices. Operating under the framework of the UK Medical Devices Regulations 2002, the document serves as a critical component of the medical device vigilance system. While it is not a report for a specific company or inspection date, it establishes the legal standards for all manufacturers operating in the UK. The main issues addressed include malfunctions, performance deterioration, or labeling inadequacies that could potentially lead to serious health issues or death. Manufacturers are required to implement systematic monitoring and must submit detailed incident reports to the MHRA within specific timeframes based on the severity of the event. Required actions include performing rigorous root cause analyses for any reported failures and executing corrective measures to mitigate future risks. By following these protocols, manufacturers ensure transparent communication with regulatory bodies, allowing for the timely identification of safety trends and the protection of the public from defective medical technology.
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.